An application made for this job — a tailored resume and cover letter that speak straight to the posting.
Regeneron is seeking a Director in Pharmacometrics in Tarrytown, NY. This leadership role involves the management of pharmacokinetic/pharmacodynamic evaluations across various projects and requires a strong quantitative background, excellent communication skills, and extensive regulatory experience.
The ideal candidate will possess a PhD and over 10 years of relevant experience, having demonstrated capabilities in delivering high-quality analyses and reports that communicate complex information effectively.
As a Director in Pharmacometrics (Quantitative Pharmacology), this individual is accountable for the delivery of support for one or more research & development programs, within their pharmacometrics discipline. In this capacity the Director is accountable for the timely and accurate delivery of needed quantitative analyses, interpretation, and messaging to PMx management, as well as the timely delivery of well‑constructed and well‑messaged reports for PMx review.
In order to be considered qualified for this role, you must have a PhD and 10+ years with a degree in Quantitative Pharmacology (Pharmacometrics) or a related field.
$205,000.00 - $341,600.00 annually
Regeneron is an equal opportunity employer and all qualified applicants will receive consideration for employment without regard to race, color, religion or belief (or lack thereof), sex, nationality, national or ethnic origin, civil status, age, citizenship status, membership of the Traveler community, sexual orientation, disability, genetic information, familial status, marital or registered civil partnership status, pregnancy or parental status, gender identity, gender reassignment, military or veteran status, or any other protected characteristic in accordance with applicable laws and regulations. The Company will also provide reasonable accommodation to the known disabilities or chronic illnesses of an otherwise qualified applicant for employment, unless the accommodation would impose undue hardship on the operation of the Company’s business.